Vaccine developer SutroVax raises $110 million in Series D funding

• Return backers include TPG Growth, Abingworth, Longitude Capital, Frazier Health Care Partners, Pivotal bioVenture Partners, Medixci, CTI Life Sciences, Roche Venture Fund, and Foresite Capital.

The bottom line: "Sutro had figured out a way to design and manufacture proteins without using living cells, as biologists have for decades. They used to build antibody-drug conjugates and recently brought multiple into the clinic. They realized, though, that it could also be important for building vaccines, a field whose potential had long been limited by how precisely you could design a protein." — Jason Mast, Endpoints News